The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
PMID: 34321170

Abstract

BACKGROUND: Sacubitril/valsartan, the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular mortality and morbidity compared to enalapril in outpatient subjects with chronic heart failure (HF) and reduced left ventricular ejection fraction (HFrEF). However, there is little real-world evidence about the efficacy of ARNIs in elderly hypertensive patients with HFrEF and comorbidities.

Authors

  • Alberto Mazza
    ESH Excellence Hypertension Centre, Internal Medicine Unit, S. Maria della Misericordia General Hospital, AULSS 5 Polesana, Rovigo, Italy. Electronic address: Xalberto.mazza@aulss5.veneto.it.
  • Danyelle M Townsend
    Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, USA.
  • Gioia Torin
    ESH Excellence Hypertension Centre, Internal Medicine Unit, S. Maria della Misericordia General Hospital, AULSS 5 Polesana, Rovigo, Italy; Unit of Internal Medicine, S. Maria della Misericordia General Hospital, AULSS 5 Polesana, Rovigo, Italy.
  • Laura Schiavon
    ESH Excellence Hypertension Centre, Internal Medicine Unit, S. Maria della Misericordia General Hospital, AULSS 5 Polesana, Rovigo, Italy; Unit of Internal Medicine, S. Maria della Misericordia General Hospital, AULSS 5 Polesana, Rovigo, Italy.
  • Alessandro Camerotto
    Department of Diagnosis and Care, Clinical Laboratory, S. Maria della Misericordia General Hospital, Rovigo, Italy.
  • Gianluca Rigatelli
    Interventional Cardiology Unit, Division of Cardiology, S. Maria della Misericordia General Hospital, AULSS 5 Polesana, Rovigo, Italy.
  • Stefano Cuppini
    Unit of Internal Medicine, S. Maria della Misericordia General Hospital, AULSS 5 Polesana, Rovigo, Italy.
  • Pietro Minuz
    Unit of Internal Medicine C, Department of Medicine, University of Verona, Verona, Italy.
  • Domenico Rubello
    Nuclear Medicine Unit, Santa Maria della Misericordia Hospital, Rovigo, Italy. Electronic address: domenico.rubello@libero.it.

Keywords

External Resources

Popular Topics
Recent Journals